Prostate News Archive
09-May-2009
The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer Patients With Bone Metastases Treated With ... (Medical News Today)
UroToday.com- Nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh and colleagues in the online version of Cancer.ZA is an intravenous bisphosphonate given to decrease skeletal related events in CaP patients with bone metastases. [click link for full article] GTX Shares Fall on Study Concern (AP via Yahoo! Finance)
Shares of biotechnology company GTX Inc. stumbled Monday on concerns on the risks involved with a late-stage study of the company's prostate cancer drug Acapodene. EPCA-2 testing more accurate way to identify cancer in the prostate (News-Medical-Net)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. Cesium-131 From IsoRay Medical (TM), Inc. Established as a Front Line Treatment for Early Stage Prostate Cancer ... (Business Wire via Yahoo! Finance)
CHICAGO----Investigators of a recent multi-institutional trial, led by principal investigator Bradley Prestidge, conclude that Cesium-131, a medical isotope used in low dose brachytherapy treatment for prostate cancer, "... has come into widespread use; and the clinical results of this trial are mature enough to be of immediate, important, practical use to practitioners."
Back to Prostate News Archive
